Annexon, Inc. Common Stock (ANNX) Stock
NASDAQ · ANNX
Fundamentals
Market cap
$758.32M
Price / Earnings ratio
-3.8x
Price / Book ratio
4.1x
Return on assets
-80.0%
Dividend amount
$0.00
Dividend yield
0.00%
Source: third-party data provider, as of October 9, 2026
Compare with ANNX
Recent news

MarketBeat
Annexon Q2 Earnings Call Highlights
ANNXAugust 12, 2026
MarketBeat
Annexon Q2 Earnings Call Highlights
ANNX

MarketBeat
Annexon Eyes ‘Win Season' With Q4 Vision Trial Data, GBS Filings Ahead
ANNXJune 9, 2026
MarketBeat
Annexon Eyes ‘Win Season' With Q4 Vision Trial Data, GBS Filings Ahead
ANNX

MarketBeat
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout
ANNXJune 4, 2026
MarketBeat
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout
ANNX

MarketBeat
Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference
ANNXMay 14, 2026
MarketBeat
Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference
ANNX
Technical indicators
- RSI 14
- 40.96
- MACD 12/26/9
- -0.17
- EMA 9 of MACD
- -0.21
- MACD histogram
- 0.04
- SMA 50
- $4.68
- Price below SMA 50
- EMA 50
- $4.54
- Price below EMA 50
- SMA 200
- $5.34
- Price below SMA 200
- EMA 200
- $4.90
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analysts
Strong Sell0
Sell0
Hold1
Buy2
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
Source: third-party data provider
Latest news

MarketBeat
Annexon Q2 Earnings Call Highlights
ANNXAugust 12, 2026
MarketBeat
Annexon Q2 Earnings Call Highlights
ANNX

MarketBeat
Annexon Eyes ‘Win Season' With Q4 Vision Trial Data, GBS Filings Ahead
ANNXJune 9, 2026
MarketBeat
Annexon Eyes ‘Win Season' With Q4 Vision Trial Data, GBS Filings Ahead
ANNX

MarketBeat
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout
ANNXJune 4, 2026
MarketBeat
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout
ANNX

MarketBeat
Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference
ANNXMay 14, 2026
MarketBeat
Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference
ANNX

Zacks Investment Research
Wall Street Analysts See a 165.52% Upside in Annexon (ANNX): Can the Stock Really Move This High?
ANNXApril 1, 2026
Zacks Investment Research
Wall Street Analysts See a 165.52% Upside in Annexon (ANNX): Can the Stock Really Move This High?
ANNX

Seeking Alpha
May MDA Breakout Stocks/ETFs Week 21 - 2023: High-Frequency Gainers To Give You An Edge
ANNXMay 21, 2023
Seeking Alpha
May MDA Breakout Stocks/ETFs Week 21 - 2023: High-Frequency Gainers To Give You An Edge
ANNX

Seeking Alpha
May MDA Breakout Stocks/ETFs Week 20 - 2023: High-Frequency Gainers To Give You An Edge
ANNXMay 14, 2023
Seeking Alpha
May MDA Breakout Stocks/ETFs Week 20 - 2023: High-Frequency Gainers To Give You An Edge
ANNX

Seeking Alpha
April MDA Breakout Stocks/ETFs Week 17 - 2023: High-Frequency Gainers To Give You An Edge
ANNXApril 23, 2023
Seeking Alpha
April MDA Breakout Stocks/ETFs Week 17 - 2023: High-Frequency Gainers To Give You An Edge
ANNX
About Annexon, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees92
CEOMr. Douglas E. Love Esq., J.D.
IPO DateJul 24, 2020
HeadquartersBrisbane, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Douglas E. Love Esq., J.D. | CEO, President & Director | 1968 |
| Ms. Jennifer Lew CPA | Executive VP, CFO & Corporate Secretary | 1973 |
| Dr. Ted Yednock Ph.D. | Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board | 1958 |
| Dr. Dean R. Artis Ph.D. | Chief Scientific Officer & Executive VP | 1961 |
| Ms. Linda A. Fitzpatrick | Chief Human Resources Officer | 1957 |
| Mr. Michael Overdorf M.B.A. | Executive VP & Chief Business Officer | 1971 |
| Mr. Henk-Andre Kroon M.D. | Senior Vice President of Translational Medicine | — |
| Dr. Jamie Dananberg M.D. | Executive VP & Chief Medical Officer | 1958 |
| Mr. Shikhar Agarwal M.B.A. | Senior VP & Head of Commercial | — |
| Dr. Sunil Mehta Pharm.D. | Senior VP of Medical Affairs | — |
Fundamentals
Valuation
Market cap$758.32M
Price-to-book value4.09
Price-earnings ratio-3.80
Return on Equity-106.00%
Return on Assets-80.00%
Earnings Per Share
Earnings Per Share$-1.14
Income Statement
Average volume3,550,901
EBITDA$-198.86M
1 year high (52w)$7.18
1 year low (52w)$2.54
Dividend
Dividend amount$0.00
Dividend yield0.00%
Source: third-party data provider, as of October 9, 2026
Technical indicators
- RSI 14
- 40.96
- MACD 12/26/9
- -0.17
- EMA 9 of MACD
- -0.21
- MACD histogram
- 0.04
- SMA 50
- $4.68
- Price below SMA 50
- EMA 50
- $4.54
- Price below EMA 50
- SMA 200
- $5.34
- Price below SMA 200
- EMA 200
- $4.90
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Buy
67% Buy
33% Hold
0% Sell
Analyst price target
- Low
- $15.00
- Average
- $20.00
- High
- $25.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -17.3 | +6.1 | -29.9 | |||||||||
| 2022 | -37.2 | -41.4 | -42.3 | -4.1 | +16.3 | +26.5 | +28.8 | +30.1 | +7.1 | -23.9 | +15.3 | -6.3 |
| 2023 | +49.1 | -26.0 | -24.7 | +34.4 | -45.1 | +17.3 | +0.0 | -22.3 | -18.9 | +5.6 | +3.8 | +94.0 |
| 2024 | -14.0 | +31.4 | +20.1 | -31.4 | +1.7 | +7.0 | +26.9 | -6.6 | +9.4 | +19.8 | -26.0 | -2.7 |
| 2025 | -30.2 | -25.0 | -19.2 | +2.8 | +9.7 | +13.2 | -2.8 | -15.9 | +47.3 | +4.3 | +42.0 | +21.5 |
| 2026 | +33.0 | -12.2 | +0.4 | +9.5 | -5.7 | +2.3 | -8.1 | -5.9 | -13.5 | -2.9 |
Compare stocks
Market cap
$758.32M
-
-
-
Price / Earnings ratio
-3.80
-
-
-
Price / Sales ratio
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
3,550,901
-
-
-
Earnings per share
$-1.14
-
-
-



